Endo International (NASDAQ:ENDP) Shares Gap Up to $2.23

Endo International PLC (NASDAQ:ENDP) (TSE:ENL)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $2.17, but opened at $2.23. Endo International shares last traded at $2.26, with a volume of 3,346,820 shares trading hands.

A number of analysts have weighed in on the company. JPMorgan Chase & Co. cut Endo International from a “neutral” rating to an “underweight” rating and set a $9.00 price target on the stock. in a research report on Monday, May 13th. Canaccord Genuity decreased their price target on Endo International from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, May 15th. Citigroup cut Endo International from a “buy” rating to a “neutral” rating and decreased their price target for the company from $19.00 to $5.00 in a report on Monday, June 17th. Mizuho reiterated a “hold” rating and issued a $6.00 price target on shares of Endo International in a report on Wednesday, August 7th. Finally, Morgan Stanley set a $2.00 price target on Endo International and gave the company a “sell” rating in a report on Friday, August 9th. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $8.48.

The firm has a fifty day moving average of $3.39 and a 200-day moving average of $6.56. The firm has a market cap of $504.86 million, a P/E ratio of 0.89 and a beta of 1.14.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Monday, August 5th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. The firm had revenue of $699.71 million for the quarter, compared to analyst estimates of $694.60 million. During the same quarter in the prior year, the firm posted $0.76 earnings per share. The company’s quarterly revenue was down 2.1% on a year-over-year basis. On average, equities analysts predict that Endo International PLC will post 2.17 EPS for the current fiscal year.

In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $3.93, for a total value of $137,357.43. Following the transaction, the director now owns 148,309 shares of the company’s stock, valued at $582,854.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.50% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ENDP. Signition LP acquired a new stake in shares of Endo International during the first quarter worth about $139,000. First Quadrant L P CA raised its stake in shares of Endo International by 94.7% during the first quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock valued at $197,000 after purchasing an additional 11,926 shares during the period. Norges Bank purchased a new stake in shares of Endo International during the fourth quarter valued at approximately $21,218,000. Factorial Partners LLC purchased a new stake in shares of Endo International during the first quarter valued at approximately $193,000. Finally, Nordea Investment Management AB raised its stake in shares of Endo International by 37.5% during the first quarter. Nordea Investment Management AB now owns 177,700 shares of the company’s stock valued at $1,427,000 after purchasing an additional 48,500 shares during the period. 93.37% of the stock is currently owned by hedge funds and other institutional investors.

Endo International Company Profile (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: How is an ETF different from a mutual fund?

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.